AN2 Therapeutics, Inc. (ANTX) Fair Value 2026

ANTX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (53/100)

Quick Summary — As of 2026-08-27, AN2 Therapeutics, Inc. (ANTX) trades at $5.74. QOC: 4.5/10. Value Trap Risk: 53/100 (WARN). 0/13 models active.

Key Facts

Ticker
ANTX
Price
$5.74
Quality Score
4.5/10
Value Trap Risk
53/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 53 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ANTX?

0 Intrinsic Value Models vs. Current Price ($5.74)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is AN2 Therapeutics, Inc. (ANTX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, AN2 Therapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ANTX?

0 of 13 models are currently active for ANTX. See which stocks rank higher →

How Does ANTX Rank in Biotechnology?

Among 620 Biotechnology stocks, ANTX ranks #450 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, AN2 Therapeutics, Inc. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ANTX a Value Trap?

CirclFi's Value Trap algorithm assigns ANTX a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for AN2 Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, AN2 Therapeutics, Inc. is rated at 4.5/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ANTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy AN2 Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PEPGPepGen Inc.QOC 4.5GANXGain Therapeutics, Inc.QOC 4.5AZTRAzitra, Inc.QOC 4.5NRXPNRx Pharmaceuticals, Inc.QOC 4.5INOInovio Pharmaceuticals, Inc.QOC 4.5HOWLWerewolf Therapeutics, Inc.QOC 4.5EPRXEupraxia Pharmaceuticals Inc.QOC 2.4TSHATaysha Gene Therapies, Inc.QOC 6.1JUNSJupiter Neurosciences, Inc.QOC 5.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PEPG · GANX · AZTR · NRXP · INO · HOWL · EPRX · TSHA · JUNS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ANTX?

6 companies across all industries closest to ANTX’s Quality of Company score of 4.5/10.

MHNCMaiden Holdings North America, Ltd.QOC 4.5HSTAHestia Insight Inc.QOC 4.5PSBDPalmer Square Capital BDC Inc.QOC 4.5AMTXAemetis, Inc.QOC 4.5GEDCTerraVolt Holdings, Inc.QOC 4.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MHNC · HSTA · PSBD · AMTX · GEDC · NVDA

Where Does ANTX Sit in CirclFi's Biotechnology Rankings?

ANTX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About AN2 Therapeutics, Inc.’s Valuation?

What is AN2 Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for AN2 Therapeutics, Inc. (ANTX). The Quality of Company score is 4.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ANTX overvalued or undervalued right now?

At $5.74, 0 of 0 active models suggest ANTX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits AN2 Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.5 mean for ANTX?

AN2 Therapeutics, Inc.'s QOC of 4.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ANTX?

CirclFi analyzes ANTX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ANTX a value trap in 2026?

AN2 Therapeutics, Inc.'s Value Trap score is 53/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns AN2 Therapeutics, Inc. (ANTX) a Quality of Company score of 4.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ANTX/ · Methodology
Primary sources for this ANTX valuation
  • Financial statements: AN2 Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001880438) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ANTX as of ; valuations recomputed .